article · Future Medicinal Chemistry
Researchers evaluated a series of spiro-oxindole compounds designed to target the interaction between the p53 tumour suppressor and MDM2 proteins. Laboratory testing demonstrated that compound 4d possesses potent, broad-spectrum antiproliferative activity across a panel of cancer cells, with an average growth inhibition value of 3.97 micromolar. Both compound 4d and compound 4i successfully disrupted the p53-MDM2 protein-protein interaction, achieving half-maximal inhibitory concentrations of 52.1 and 95.2 nanomolar, respectively. Molecular investigations showed that compound 4d suppresses the expression of wild-type p53 in MCF-7 breast cancer cells to a greater extent than mutant p53 in MDA-MB231 cells. In addition, computational molecular docking studies revealed how these target molecules physically interact with the key p53 binding site on MDM2.
Disrupting the interaction between p53 and MDM2 is an established strategy for controlling abnormal cancer cell growth. By proving effective at nanomolar concentrations and demonstrating antiproliferative effects in breast cancer cell models, these compounds provide a clear chemical starting point for future oncology drug discovery efforts.
This work represents very early-stage discovery chemistry that could be relevant to pharmaceutical companies and biotechnology developers focusing on oncology therapeutics. The active compounds serve as potential leads for small-molecule drug development targeting the p53-MDM2 pathway. However, being limited to in vitro assays and computational docking, the molecules remain far from practical clinical use and require extensive preclinical testing and optimisation.
AI-generated from the published abstract. Always read the original work before citing.
Compound 4d exhibited potent and broad spectrum of antiproliferative activity with full panel GI<sub>50</sub> (MG-MID) value of 3.97 μM. Compounds 4d and 4i inhibited p53-MDM2 protein-protein interaction with IC<sub>50</sub> = 52.1 and 95.2 nM, respectively. Compound 4d inhibits the expression of wild p53 in MCF-7 more than mutant p53 in MDA-MB231 at the molecular level. Molecular docking studies illustrated the possible interaction of the target spiro-oxindoles with the p53 binding site on MDM2.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4155/fmc-2018-0288
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
